Department of Emergency Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Acad Emerg Med. 2012 Nov;19(11):1255-60. doi: 10.1111/acem.12016.
This study was conducted to determine if there is practice variation for emergency physicians' (EPs) management of recent-onset atrial fibrillation (RAF) in various world regions (Canada, United States, United Kingdom, and Australasia).
The authors completed a mail and e-mail survey of members from four national emergency medicine (EM) associations. One prenotification letter and three survey letters were sent to members of the Canadian Association of Emergency Physicians (CAEP; Canada-1,177 members surveyed), American College of Emergency Physicians (ACEP; United States-500), College of Emergency Medicine UK (CEM; United Kingdom-1,864), and Australasian College for Emergency Medicine (ACEM; Australasia-1,188) as per the modified Dillman technique. The survey contained 23 questions related to the management of adult patients with symptomatic RAF (either a first episode or paroxysmal-recurrent) where onset is less than 48 hours and cardioversion is considered a treatment option. Data were analyzed using descriptive and chi-square statistics.
Response rates were as follows: overall, 40.5%; Canada, 43.0%; United States, 50.1%; United Kingdom, 38.1%; and Australasia, 38.0%. Physician demographics were as follows: 72% male and mean (±SD) age 41.7 (±8.39) years. The proportions of physicians attempting rate control as their initial strategy are United States, 94.0%; Canada, 70.7%; Australasia, 61.1%; and United Kingdom, 43.1% (p < 0.0001). Diltiazem is the predominant agent for rate control in Canada (65.36%) and the United States (95.22%), while metoprolol is used in Australasia (65.94%) and the United Kingdom (67.64%). Cardioversion is attempted at varying rates in Canada (65.9%), Australasia (49.9%), United Kingdom (49.5%), and the United States (25.9%) (p < 0.0001). Pharmacologic cardioversion is attempted first in all regions, with the preferred drug being procainamide in Canada (61.93%) and amiodarone in Australasia (63.39%), the United Kingdom (47.97%), and the United States (22.41%; p < 0.0001). If drugs fail, electrical cardioversion is then attempted in Canada (70.64%), Australasia (46.19%), the United States (29.69%), and the United Kingdom (27.78%; p < 0.0001).
There is much variation in emergency department (ED) management of RAF among world regions, most markedly for use of rate versus rhythm control, choice of drugs, and use of electrical cardioversion. Canadians are more likely to use an aggressive approach for management of RAF, whereas Americans are more likely to employ conservative management. U.K. and Australasian EPs fall somewhere in the middle. These differences demonstrate the need for better evidence, or better synthesis of existing knowledge, to create guidelines to guide ED management of this common dysrhythmia.
本研究旨在确定在加拿大、美国、英国和澳大拉西亚等不同世界区域,急诊医生(EP)对新发心房颤动(RAF)的管理是否存在实践差异。
作者对四个国家急诊医学(EM)协会的成员进行了邮件和电子邮件调查。按照改良的 Dillman 技术,向加拿大急诊医师协会(CAEP;加拿大-1177 名受访者)、美国急诊医师学院(ACEP;美国-500 名)、英国紧急医学学院(CEM;英国-1864 名)和澳大利亚紧急医学学院(ACEM;澳大利亚-1188 名)的成员发送了一封预通知信和三封调查信。调查包含 23 个问题,涉及管理有症状 RAF(首次发作或阵发性/复发性)的成年患者,RAF 发作时间少于 48 小时且考虑电复律为治疗选择。使用描述性和卡方统计数据进行数据分析。
总体应答率为 40.5%;加拿大为 43.0%;美国为 50.1%;英国为 38.1%;澳大利亚为 38.0%。医生的人口统计学特征如下:72%为男性,平均(±SD)年龄为 41.7(±8.39)岁。试图以控制心率作为初始策略的医生比例为:美国 94.0%;加拿大 70.7%;澳大利亚 61.1%;英国 43.1%(p<0.0001)。加拿大和美国首选地尔硫䓬(分别为 65.36%和 95.22%)控制心率,而在澳大利亚和英国则使用美托洛尔(分别为 65.94%和 67.64%)。加拿大(65.9%)、澳大利亚(49.9%)、英国(49.5%)和美国(25.9%)尝试电复律的比例各不相同(p<0.0001)。所有地区均首先尝试药物电复律,首选药物为加拿大(61.93%)和澳大利亚(63.39%)的普罗卡因胺,英国(47.97%)和美国(22.41%)的胺碘酮(p<0.0001)。如果药物治疗失败,则在加拿大(70.64%)、澳大利亚(46.19%)、美国(29.69%)和英国(27.78%)尝试电复律(p<0.0001)。
世界各地区在 RAF 的急诊科管理方面存在很大差异,最明显的是心率与节律控制的使用、药物选择和电复律的使用。加拿大人更倾向于积极管理 RAF,而美国人则更倾向于采用保守的管理方法。英国和澳大利亚的 EP 则处于两者之间。这些差异表明,需要更好的证据或更好地综合现有知识,以制定指南来指导 RAF 的常见心律失常的急诊科管理。